Novo Nordisk’s Ozempic already is poised to disrupt a range of industries via its weight-loss benefits. Now it threatens companies which treat kidney failure.
Novo Nordisk A/S (NYSE:NVO – Get Free Report)’s share price rose 2.3% during trading on Wednesday . The stock traded as high as $89.94 and last traded at $89.80. Approximately 381,972 shares were traded during trading, a decline of 88% from the average daily volume of 3,097,575 shares. The stock had previously closed at $87.78. […]